Epilepsy natural history, complications and prognosis
|
Epilepsy Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Epilepsy natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Epilepsy natural history, complications and prognosis |
|
FDA on Epilepsy natural history, complications and prognosis |
|
CDC on Epilepsy natural history, complications and prognosis |
|
Epilepsy natural history, complications and prognosis in the news |
|
Blogs on Epilepsy natural history, complications and prognosis |
|
Risk calculators and risk factors for Epilepsy natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Natural History, Complications, and Prognosis
Natural History
- The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of epilepsy include:
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [--]%.
- Depending on the extent of the [tumor/disease progression] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.
References
- ↑ Buck D, Baker GA, Jacoby A, Smith DF, Chadwick DW (April 1997). "Patients' experiences of injury as a result of epilepsy". Epilepsia. 38 (4): 439–44. PMID 9118849.
- ↑ van den Broek M, Beghi E (January 2004). "Morbidity in patients with epilepsy: type and complications: a European cohort study". Epilepsia. 45 (1): 71–6. PMID 14692910.
- ↑ Pack AM, Olarte LS, Morrell MJ, Flaster E, Resor SR, Shane E (April 2003). "Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs". Epilepsy Behav. 4 (2): 169–74. PMID 12697142.